Phosphorylation of pleckstrin increases proinflammatory cytokine secretion by mononuclear phagocytes in diabetes mellitus

Journal of Immunology

Volumn 179, Issue 1, 2007, Pages 647-654

  Ding, Yong ^a   Kantarci, Alpdogan ^a   Badwey, John A ^b   Hasturk, Hatice ^a   Malabanan, Alan ^c   Van Dyke, Thomas E ^a  

^a BOSTON UNIVERSITY   (United States)

^b HARVARD MEDICAL SCHOOL   (United States)

^c BOSTON UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; HEMOGLOBIN A1C; INTERLEUKIN 1BETA; PLECKSTRIN; PROTEIN KINASE C; TUMOR NECROSIS FACTOR ALPHA;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DIABETES MELLITUS; ENZYME ACTIVATION; HUMAN; HUMAN CELL; IMMUNOBLOTTING; IMMUNOPRECIPITATION; MASS SPECTROMETRY; MONONUCLEAR CELL; PHAGOCYTE; PHAGOCYTOSIS; PRIORITY JOURNAL; PROTEIN PHOSPHORYLATION; RESPIRATORY BURST; SIGNAL TRANSDUCTION;

EID: 34250831438     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.179.1.647     Document Type: Article

References (59)

1. Hink, U., H. Li, H. Mollnau, M. Oelze, E. Matheis, M. Hartmann, M. Skatchkov, F. Thaiss, R. A. Stahl, A. Warnholtz, et al. 2001. Mechanisms underlying endothelial dysfunction in diabetes mellitus. Circ. Res. 88: E14-E22.
2. Ishii, H., D. Koya, and G. L. King. 1998. Protein kinase C activation and its role in the development of vascular complications in diabetes mellitus. J Mol. Med. 76: 21-31.
3. Koya, D., and G. L. King. 1998. Protein kinase C activation and the development of diabetic complications. Diabetes 47: 859-866.
4. Nishizuka, Y. 1992. Intracellular signaling by hydrolysis of phospholipids and activation of protein kinase C. Science 258: 607-614.
5. Nishizuka, Y. 1995. Protein kinase C and lipid signaling for sustained cellular responses. FASEB J. 9: 484-496.
6. Liscovitch, M., and L. C. Cantley. 1994. Lipid second messengers. Cell 77: 329-334.
7. Allen, L. H., and A. Aderem. 1995. A role for MARCKS, the α isozyme of protein kinase C and myosin I in zymosan phagocytosis by macrophages. J. Exp. Med. 182: 829-840.
8. Brumell, J. H., J. C. Howard, K. Craig, S. Grinstein, A. D. Schreiber, and M. Tyers. 1999. Expression of the protein kinase C substrate pleckstrin in macrophages: association with phagosomal membranes. J. Immunol. 163: 3388-3395.
9. Wautier, M. P., O. Chappey, S. Corda, D. M. Stern, A. M. Schmidt, and J. L. Wautier. 2001. Activation of NADPH oxidase by AGE links oxidant stress to altered gene expression via RAGE. Am. J. Physiol. 280: E685-E694.
10. Inoguchi, T., R. Battan, E. Handler, J. R. Sportsman, W. Heath, and G. L. King. 1992. Preferential elevation of protein kinase C isoform β II and diacylglycerol levels in the aorta and heart of diabetic rats: differential reversibility to glycemic control by islet cell transplantation. Proc. Natl. Acad. Sci. USA 89: 11059-11063.
11. Koya, D., M. R. Jirousek, Y. W. Lin, H. Ishii, K. Kuboki, and G. L. King. 1997. Characterization of protein kinase C β isoform activation on the gene expression of transforming growth factor-β, extracellular matrix components, and prostanoids in the glomeruli of diabetic rats. J. Clin. Invest. 100: 115-126.
12. Shiba, T., T. Inoguchi, J. R. Sportsman, W. F. Heath, S. Bursell, and G. L. King. 1993. Correlation of diacylglycerol level and protein kinase C activity in rat retina to retinal circulation. Am. J. Physiol. 265: E783-E793.
13. Aiello, L. P., S. E. Bursell, A. Clermont, E. Duh, H. Ishii, C. Takagi, F. Mori, T. A. Ciulla, K. Ways, M. Jirousek, et al. 1997. Vascular endothelial growth factor-induced retinal permeability is mediated by protein kinase C in vivo and suppressed by an orally effective β-isoform-selective inhibitor. Diabetes 46: 1473-1480.
14. Ways, D. K., and M. J. Sheetz. 2000. The role of protein kinase C in the development of the complications of diabetes. Vitam. Horm. 60: 149-193.
15. Way, K. J., N. Katai, and G. L. King. 2001. Protein kinase C and the development of diabetic vascular complications. Diabetes Med. 18: 945-959.
16. Sheetz, M. J., and G. L. King. 2002. Molecular understanding of hyperglycemia's adverse effects for diabetic complications. J. Am. Med. Assoc. 288: 2579-2588.
17. Ha, H., M. R. Yu, Y. J. Choi, and H. B. Lee. 2001. Activation of protein kinase c-δ and c-ε by oxidative stress in early diabetic rat kidney. Am. J. Kidney Dis. 38: S204-S207.
18. Beauchamp, M. C., S. E. Michaud, L. Li, M. R. Sartippour, and G. Renier. 2004. Advanced glycation end products potentiate the stimulatory effect of glucose on macrophage lipoprotein lipase expression. J. Lipid Res. 45: 1749-1757.
19. Kislinger, T., C. Fu, B. Huber, W. Qu, A. Taguchi, S. Du Yan, M. Hofmann, S. F. Yan, M. Pischetsrieder, D. Stern, and A. M. Schmidt. 1999. N(ε)-(carboxymethyl)lysine adducts of proteins are ligands for receptor for advanced glycation end products that activate cell signaling pathways and modulate gene expression. J. Biol. Chem. 274: 31740-31749.
20. Hofmann, M. A., S. Drury, C. Fu, W. Qu, A. Taguchi, Y. Lu, C. Avila, N. Kambham, A. Bierhaus, P. Nawroth, et al. 1999. RAGE mediates a novel proinflammatory axis: a central cell surface receptor for S100/calgranulin polypeptides. Cell 97: 889-901.
21. Yan, S. D., X. Chen, J. Fu, M. Chen, H. Zhu, A. Roher, T. Slattery, L. Zhao, M. Nagashima, J. Morser, et al. 1996. RAGE and amyloid-β peptide neurotoxicity in Alzheimer's disease. Nature 382: 685-691.
22. Brownlee, M., A. Cerami, and H. Vlassara. 1988. Advanced glycosylation end products in tissue and the biochemical basis of diabetic complications. N. Engl. J. Med. 318: 1315-1321.
23. Zimmer, D. B., J. Chessher, G. L. Wilson, and W. E. Zimmer. 1997. S100A1 and S100B expression and target proteins in type I diabetes. Endocrinology 138: 5176-5183.
24. Kosaki, A., T. Hasegawa, T. Kimura, K. Iida, J. Hitomi, H. Matsubara, Y. Mori, M. Okigaki, N. Toyoda, H. Masaki, et al. 2004. Increased plasma S100A12 (EN-RAGE) levels in patients with type 2 diabetes. J. Clin. Endocrinol. Metab. 89: 5423-5428.
25. Hudson, B. I., and A. M. Schmidt. 2004. RAGE: a novel target for drug intervention in diabetic vascular disease. Pharm. Res. 21: 1079-1086.
26. Vlassara, H., M. Brownlee, K. R. Manogue, C. A. Dinarello, and A. Pasagian. 1988. Cachectin/TNF and IL-1 induced by glucose-modified proteins: role in normal tissue remodeling. Science 240: 1546-1548.
27. Sartippour, M. R., and G. Renier. 2000. Upregulation of macrophage lipoprotein lipase in patients with type 2 diabetes: role of peripheral factors. Diabetes 49: 597-602.
28. Clausell, N., P. Kalil, A. Biolo, S. Molossi, and M. Azevedo. 1999. Increased expression of tumor necrosis factor-α in diabetic macrovasculopathy. Cardiovasc. Pathol. 8: 145-151.
29. Pfeiffer, A., J. Janott, M. Mohlig, M. Ristow, H. Rochlitz, K. Busch, H. Schatz, and E. Schifferdecker. 1997. Circulating tumor necrosis factor α is elevated in male but not in female patients with type II diabetes mellitus. Horm. Metab. Res. 29: 111-114.
30. Limb, G. A., H. Soomro, S. Janikoun, R. D. Hollifield, and J. Shilling. 1999. Evidence for control of tumour necrosis factor-α (TNF-α) activity by TNF receptors in patients with proliferative diabetic retinopathy. Clin. Exp. Immunol. 115: 409-414.
31. Limb, G. A., A. H. Chignell, W. Green, F. LeRoy, and D. C. Dumonde. 1996. Distribution of TNF α and its reactive vascular adhesion molecules in fibrovascular membranes of proliferative diabetic retinopathy. Br. J. Ophthalmol. 80: 168-173.
32. Joussen, A. M., V. Poulaki, N. Mitsiades, B. Kirchhof, K. Koizumi, S. Dohmen, and A. P. Adamis. 2002. Nonsteroidal anti-inflammatory drugs prevent early diabetic retinopathy via TNF-α suppression. FASEB J. 16: 438-440.
33. Doganay, S., C. Evereklioglu, H. Er, Y. Turkoz, A. Sevinc, N. Mehmet, and H. Savli. 2002. Comparison of serum NO, TNF-α, LL 1β, sIL-2R, IL-6 and IL-8 levels with grades of retinopathy in patients with diabetes mellitus. Eye 16: 163-170.
34. Moriwaki, Y., T. Yamamoto, Y. Shibutani, E. Aoki, Z. Tsutsumi, S. Takahashi, H. Okamura, M. Koga, M. Fukuchi, and T. Hada. 2003. Elevated levels of interleukin-18 and tumor necrosis factor-a in serum of patients with type 2 diabetes mellitus: relationship with diabetic nephropathy. Metabolism 52: 605-608.
35. Hasegawa, G., K. Nakano, M. Sawada, K. Uno, Y. Shibayama, K. Ienaga, and M. Kondo. 1991. Possible role of tumor necrosis factor and interleukin-1 in the development of diabetic nephropathy. Kidney Int. 40: 1007-1012.
36. Goova, M. T., J. Li, T. Kislinger, W. Qu, Y. Lu, L. G. Bucciarelli, S. Nowygrod, B. M. Wolf, X. Caliste, S. F. Yan, et al. 2001. Blockade of receptor for advanced glycation end-products restores effective wound healing in diabetic mice. Am. J. Pathol. 159: 513-525.
37. Ohira, T., Q. Zhan, Q. Ge, T. VanDyke, and J. A. Badwey. 2003. Protein phosphorylation in neutrophils monitored with phosphospecific antibodies. J. Immunol. Methods 281: 79-94.
38. National Diabetes Data Group. 1979. Classification and diagnosis of diabetes mellitus and other categories of glucose intolerance. Diabetes 28: 1039-1057.
39. Clark, M. J., Jr., J. J. Sterrett, and D. S. Carson. 2000. Diabetes guidelines: a summary and comparison of the recommendations of the American Diabetes Association, Veterans Health Administration, and American Association of Clinical Endocrinologists. Clin. Ther. 22: 899-910.
40. Koeffler, H. P., T. Amatruda, N. Ikekawa, Y. Kobayashi, and H. F. DeLuca. 1984. Induction of macrophage differentiation of human normal and leukemic myeloid stem cells by 1,25-dihydroxyvitamin D3 and its fluorinated analogues. Cancer Res. 44: 5624-5628.
41. 3 induce on THP-1 cells distinct patterns of cell surface antigen expression, cytokine production, and responsiveness to contact with activated T cells. J. Immunol. 149: 2040-2046.
42. Wolfson, M., L. C. McPhail, V. N. Nasrallah, and R. Snyderman. 1985. Phorbol myristate acetate mediates redistribution of protein kinase C in human neutrophils: potential role in the activation of the respiratory burst enzyme. J. Immunol. 135: 2057-2062.
43. Shibata, Y., Y. Abiko, H. Arii, M. Sone, and H. Takiguchi. 1987. Rapid procedure for preparation of macrophage plasma membrane. Int. J. Biochem. 19: 489-493.
44. Barua, R. S., J. A. Ambrose, S. Srivastava, M. C. DeVoe, and L. J. Eales-Reynolds. 2003. Reactive oxygen species are involved in smoking-induced dysfunction of nitric oxide biosynthesis and upregulation of endothelial nitric oxide synthase: an in vitro demonstration in human coronary artery endothelial cells. Circulation 107: 2342-2347.
45. Brumell, J. H., K. L. Craig, D. Ferguson, M. Tyers, and S. Grinstein. 1997. Phosphorylation and subcellular redistribution of pleckstrin in human neutrophils. J. Immunol. 158: 4862-4871.
46. - generation by mononuclear phagocytes in diabetes. J. Leukocyte Biol. 81: 520-527.
47. Meier, M., and G. L. King. 2000. Protein kinase C activation and its pharmacological inhibition in vascular disease. Vasc. Med. 5: 173-185.
48. Gailani, D., T. C. Fisher, D. C. Mills, and D. E. Macfarlane. 1990. P47 phosphoprotein of blood platelets (pleckstrin) is a major target for phorbol ester-induced protein phosphorylation in intact platelets, granulocytes, lymphocytes, monocytes and cultured leukaemic cells: absence of P47 in non-haematopoietic cells. Br. J. Haematol. 74: 192-202.
49. Abrams, C. S., W. Zhao, E. Belmonte, and L. F. Brass. 1995. Protein kinase C regulates pleckstrin by phosphorylation of sites adjacent to the N-terminal pleckstrin homology domain. J. Biol. Chem. 270: 23317-23321.
50. 117 by protein kinase C. Biochem. J. 314(Pt. 3): 937-942.
51. Civera, C., B. Simon, G. Stier, M. Sattler, and M. J. Macias. 2005. Structure and dynamics of the human pleckstrin DEP domain: distinct molecular features of a novel DEP domain subfamily. Proteins 58: 354-366.
52. Berg, T. J., K. Dahl-Jorgensen, P. A. Torjesen, and K. F. Hanssen. 1997. Increased serum levels of advanced glycation end products (AGEs) in children and adolescents with IDDM. Diabetes Care 20: 1006-1008.
53. Kilhovd, B. K., T. J. Berg, K. I. Birkeland, P. Thorsby, and K. F. Hanssen. 1999. Serum levels of advanced glycation end products are increased in patients with type 2 diabetes and coronary heart disease. Diabetes Care 22: 1543-1548.
54. Brett, J., A. M. Schmidt, S. D. Yan, Y. S. Zou, E. Weidman, D. Pinsky, R. Nowygrod, M. Neeper, C. Przysiecki, A. Shaw, et al. 1993. Survey of the distribution of a newly characterized receptor for advanced glycation end products in tissues. Am. J. Pathol. 143: 1699-1712.
55. Kirstein, M., J. Brett, S. Radoff, S. Ogawa, D. Stern, and H. Vlassara. 1990. Advanced protein glycosylation induces transendothelial human monocyte chemotaxis and secretion of platelet-derived growth factor: role in vascular disease of diabetes and aging. Proc. Natl. Acad. Sci. USA 87: 9010-9014.
56. Khechai, F., V. Ollivier, F. Bridey, M. Amar, J. Hakim, and D. de Prost. 1997. Effect of advanced glycation end product-modified albumin on tissue factor expression by monocytes: role of oxidant stress and protein tyrosine kinase activation. Arterioscler. Thromb. Vasc. Biol. 17: 2885-2890.
57. Karima, M., A. Kantarci, T. Ohira, H. Hasturk, V. L. Jones, B. H. Nam, A. Malabanan, P. C. Trackman, J. A. Badwey, and T. E. Van Dyke. 2005. Enhanced superoxide release and elevated protein kinase C activity in neutrophils from diabetic patients: association with periodontitis. J. Leukocyte Biol. 78: 862-870.
58. Nishikawa, K., A. Toker, F. J. Johannes, Z. Songyang, and L. C. Cantley. 1997. Determination of the specific substrate sequence motifs of protein kinase C isozymes. J. Biol. Chem. 272: 952-960.
59. Pearson, R. B., and B. E. Kemp. 1991. Protein kinase phosphorylation site sequences and consensus specificity motifs: tabulations. Methods Enzymol. 200: 62-81.